1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Vitrolife AB (publ)

Vitrolife AB (publ)

VTRLY
Vitrolife AB (publ)US flagOther OTC
9.50
USD
- -
- -
1.29BMarket Cap
Vitrolife AB (publ)
VTRLY
(Other OTC)

Recent

price

9.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.04
3.15
3.7
4.57
5.11
6.65
7.89
9.64
10.61
13.64
11.47
14.67
23.89
25.94
26.65
25.4
26.13
Revenue per Share
0.3
0.31
3.41
0.57
1.09
1.68
1.75
2.43
2.85
3.53
2.64
2.97
2.91
-28.44
3.79
-37.01
3.36
Basic EPS, GAAP
0.07
0.16
0.43
0.98
1.37
1.57
1.54
2.78
1.56
3.01
3.1
2.8
4.05
4.71
5.21
2.87
4.39
Free Cash Flow per Basic Share
0.1
0.12
0.14
0.12
0.2
0.3
0.48
0.53
0.75
0.85
- -
0.77
0.81
0.85
1
1.1
1.1
Dividend per Share
3.33
3.51
2.8
3.17
6.46
7.77
9.38
11.29
13.75
16.53
18.54
113.12
123.56
93.93
100.7
58.28
98.05
Book Value per Share
1.43
1.42
0.62
1.09
1.29
3.02
3.4
5.69
7.05
9.36
12.07
-16.43
-13.19
-8.72
-6.08
-2.84
-5.39
Tangible Book Value per Share
98
98
98
99
100
109
109
109
109
109
109
115
135
135
135
135
135
Basic Weighted Avg Shares
298
308
362
453
511
722
856
1,046
1,151
1,480
1,246
1,681
3,234
3,512
3,609
3,440
3,539
Sales/Revenue/Turnover
11.18
7.06
13.84
17.41
26.61
28.87
28.97
32.82
33.79
32.98
30.17
25.46
20.01
21.01
21.95
16.69
19.36
Operating Margin (%)
- -
17
19
35
23
53
54
67
85
99
84
109
396
425
442
427
121
Depreciation Expense
29
30
334
56
109
183
190
264
310
383
287
341
394
-3,851
513
-5,012
455
Net Income, GAAP
29.26
32.06
46.63
28.94
25.49
19.17
23.19
22.38
22.05
22.09
21.39
25.22
26.63
- -
23.74
- -
- -
Effective Tax Rate (%)
9.72
9.86
92.2
12.43
21.37
25.31
22.24
25.2
26.9
25.86
23.03
20.29
12.18
-109.65
14.21
-145.7
12.86
Profit Margin (%)
70
86
63
88
149
283
317
575
698
948
1,237
453
951
1,357
1,652
1,477
1,542
Working Capital
41
56
58
22
60
36
- -
- -
- -
61
49
2,026
2,043
1,942
1,929
1,562
1,840
LT Debt
326
344
279
316
703
845
1,020
1,229
1,496
1,798
2,017
15,341
16,740
12,723
13,641
7,895
13,282
Total Equity
6.72
3.7
6.82
15.34
17.12
19.35
18.98
22.93
21.95
22.25
14.83
3.21
2.58
- -
3.95
- -
4.48
Return on Invested Capital (%)
10.12
9.22
87.56
16.14
19.16
21.81
19.49
23
22.68
22.76
14.54
3.47
2.32
- -
3.82
- -
2.99
Return on Capital (%)
9.08
9.08
107.54
19.02
21.5
23.68
20.46
23.5
22.78
23.29
15.07
3.93
2.46
-26.15
3.89
-46.55
3.45
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
160
151
153
LT Borrowings
1,837
1,710
1,758
LT Finance Leases
92
90
82
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
135
135
135
Market Capitalization
28,218
24,577
19,184

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,357
2,279
2,183
Cash, Cash Equivalents & STI
1,135
1,054
921
Accounts Receivable, Net
648
634
635
Inventories
422
413
430
Total Current Liabilities
705
605
641
Payables & Accruals
- -
- -
- -
ST Debt
160
151
153
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.61%
122.16%
-42.12%
Free Cash Flow
17.82%
9.64%
-44.96%
Net Income, GAAP
-217.47%
-446.66%
-1,077%
Sales/Revenue/Turnover
19.75%
26.81%
-4.68%
Total Cash Common Dividend
- -
10.54%
10.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
841
941
867
959
3,609
2025
842
871
891
- -
3,440
2026
807
857
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.85
1.06
0.86
1.03
3.79
2025
0.74
0.74
-39.24
- -
-37.01
2026
0.75
0.95
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
- -
- -
1
2025
- -
1.1
- -
- -
1.1
2026
- -
1.1
- -
- -
- -
Similar Companies
ScandiDos AB (publ) (SDOS.ST)
Imagin Medical Inc. (IMEXF)
Soliton, Inc. (SOLY)
Accelerate Diagnostics, Inc. (AXDX)
BBS-Bioactive Bone Substitutes Oyj (BONEH.HE)
Theradiag S.A. (ALTER.PA)
Business
Vitrolife AB (publ) develops, manufactures and markets medical devices, consumables and genetic services for assisted reproduction and reproductive health to IVF clinics worldwide. The company offers a comprehensive portfolio of products including IVF media and oil such as G-Series and Sydney IVF media; EmbryoGlue embryo transfer medium; time-lapse incubation systems including EmbryoScope and Primo Vision with associated evaluation tools; micromanipulation pipettes; oocyte retrieval needles; sperm processing solutions; cryopreservation equipment and media; labware comprising dishes, tubes and pipettes; laser and imaging systems such as Octax; preimplantation genetic testing services; and digital witnessing systems like eWitness integrated with electronic medical records; as well as procedural solutions for vitrification, embryo transfer and temperature control. Vitrolife operates globally across Europe, Middle East and Africa; Americas; Asia-Pacific including Japan and China; and serves fertility clinics seeking to improve treatment outcomes and operational efficiency. Founded in 1989 and headquartered in Gothenburg, Sweden, the company employs approximately 1,150 people and was formerly known as Scandinavian IVF Science before changing its name in 1998. Recent developments include the May 2024 acquisition of eFertility to enhance digitalization and standardization in IVF workflows through witnessing systems and EMR integration; regulatory approvals and launches of embryoCath and ultra-rapid warm blast products; execution of a new five-year corporate strategy emphasizing R&D investment doubling, platform integration across IVF processes, growth in key markets like the US and China, and manufacturing automation; alongside Q3 2025 organic sales growth of 5% driven by Americas and EMEA performance.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Vitrolife AB (publ) (VTRLY) Q2 2026 Earnings Call Transcript

  • prnewswire.com

    Report from the Annual General Meeting of Vitrolife AB (publ)

  • seekingalpha.com

    Vitrolife AB (publ) (VTRLY) Q1 2026 Earnings Call Transcript

  • prnewswire.com

    Vitrolife AB (publ) - Interim report Q1, 2026: Strong growth in Consumables and Technologies

  • prnewswire.com

    Notice of the Annual General Meeting of Vitrolife AB (publ)

  • seekingalpha.com

    Vitrolife AB (publ) (VTRLY) Q4 2025 Earnings Call Transcript

  • prnewswire.com

    Vitrolife AB (publ) - Fourth quarter and full year report 2025

  • defenseworld.net

    Vitrolife AB (publ) (OTCMKTS:VTRLY) Shares Up 1.6% – Here’s What Happened

  • defenseworld.net

    Vitrolife AB (publ) (OTCMKTS:VTRLY) Stock Price Down 16.4% – Should You Sell?

  • prnewswire.com

    Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026